{"id":38990,"date":"2013-09-19T16:10:34","date_gmt":"2013-09-19T20:10:34","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=38990"},"modified":"2013-09-19T16:10:34","modified_gmt":"2013-09-19T20:10:34","slug":"clopidogrels-benefits-seen-mainly-in-smokers","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2013\/09\/19\/clopidogrels-benefits-seen-mainly-in-smokers\/","title":{"rendered":"Clopidogrel&#8217;s Benefits Seen Mainly in Smokers"},"content":{"rendered":"<p>Clopidogrel appears to offer more protection against cardiovascular events among smokers than nonsmokers, according to <a href=\"http:\/\/www.bmj.com\/content\/347\/bmj.f5307\">a systematic review in <em>BMJ<\/em><\/a>.<\/p>\n<p>Researchers examined data from six randomized trials comparing clopidogrel (alone or with aspirin) with control treatments (namely, aspirin alone or lower-dose clopidogrel plus aspirin). Nearly 75,000 patients with established cardiovascular disease, 30% of whom were smokers, were included.<\/p>\n<p>Among smokers, clopidogrel was associated with a 25% reduction in the composite outcome of cardiovascular death, MI, or stroke; however, among nonsmokers, it conferred only an 8% reduction. (In a separate analysis, they also found that prasugrel or ticagrelor &#8220;seemed to be more efficacious&#8221; than clopidogrel in smokers and &#8220;marginally more efficacious&#8221; in nonsmokers.)<\/p>\n<p>The researchers conclude: &#8220;Different risk-benefit considerations might be required for smokers and nonsmokers.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Clopidogrel appears to offer more protection against cardiovascular events among smokers than nonsmokers, according to a systematic review in BMJ. Researchers examined data from six randomized trials comparing clopidogrel (alone or with aspirin) with control treatments (namely, aspirin alone or lower-dose clopidogrel plus aspirin). Nearly 75,000 patients with established cardiovascular disease, 30% of whom were [&hellip;]<\/p>\n","protected":false},"author":577,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[495,1,7],"tags":[1488,334,1376,402],"class_list":["post-38990","post","type-post","status-publish","format-standard","hentry","category-anticoagulation-2","category-general","category-prevention","tag-cardiovascular-events","tag-clopidogrel","tag-risk-reduction","tag-smoking"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/38990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/577"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=38990"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/38990\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=38990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=38990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=38990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}